Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Assets: 2016-2024

Historic Assets for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Dec 2024 value amounting to $527.7 million.

  • Rocket Pharmaceuticals' Assets fell 6.52% to $368.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $368.0 million, marking a year-over-year decrease of 6.52%. This contributed to the annual value of $527.7 million for FY2024, which is 6.82% down from last year.
  • Rocket Pharmaceuticals' Assets amounted to $527.7 million in FY2024, which was down 6.82% from $566.3 million recorded in FY2023.
  • Rocket Pharmaceuticals' 5-year Assets high stood at $590.8 million for FY2020, and its period low was $497.0 million during FY2021.
  • Over the past 3 years, Rocket Pharmaceuticals' median Assets value was $551.8 million (recorded in 2022), while the average stood at $548.6 million.
  • Its Assets has fluctuated over the past 5 years, first skyrocketed by 58.77% in 2020, then fell by 15.88% in 2021.
  • Rocket Pharmaceuticals' Assets (Yearly) stood at $590.8 million in 2020, then dropped by 15.88% to $497.0 million in 2021, then increased by 11.02% to $551.8 million in 2022, then climbed by 2.63% to $566.3 million in 2023, then decreased by 6.82% to $527.7 million in 2024.